InvestorsHub Logo
Followers 66
Posts 12688
Boards Moderated 0
Alias Born 06/03/2015

Re: Investor2014 post# 448888

Tuesday, 01/23/2024 12:51:20 PM

Tuesday, January 23, 2024 12:51:20 PM

Post# of 459839
That would be a FUD spin of the headline. However, a more accurate interpretation is the enlightened view of a broader platform (beyond 2-73) based on additional studies. This, in addition to the successful trial results of 2-73 that will likely lead to approvals this year for AD, as well as Rett, if the Rett Syndrome org carries any weight. The overall QoL evidence is far too strong to deny. And the EMA has already reviewed the data and recommended an MAA submission for full approval.

The evidence is quite strong against your continued FUD narratives.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News